Table 2.
Outcomes of immunogenicity studies of influenza vaccination in adult patients with hematological tumors which recommend vaccination.
| ARTICLE’S TITLE | SELECTED POPULATION | TREATMENT AT TIME OF VACCINATION | MEASURE OF EFFICACY | RESPONSE | OUTCOMES |
|---|---|---|---|---|---|
| Response to influenza A vaccine among high-risk patients37 | Hematologic malignancies (n = 31); controls (n = 41) | Maintenance treatment (n = 14); cyclic chemotherapy (n = 7); untreated (n = 10) | 4 fold rise increase in HI titer | 52% v 78% for controls in first strain; 32% v 56% for controls in second strain | Vaccination recommended |
| Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy23 | Lymphoma (n = 41) | Doxorubicin (66%); cyclophos (56%); etoposide (46%); ara-c(39%); cisplatin (39%);bleomycin (37%); VCR (29%); mesna (29%); steroids (100%); some alpha-interferon | 4 fold rise increase in HI titer | 42% after single shot; 50% after second vaccination | Recommended vaccination of 2 doses regimen |
| Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma38 | NHL (n = 32); controls (n = 32) | Immunosuppressive drugs (n = 16); “not subjected to this therapy” (n = 11); unaccounted for (n = 5) | HI MFI, seroprotection, RR | MFI from 9.3 to 12.2 v27.6 to 44.3 for controls; lymphoma Sero-protection rate increased from 59% to 69% v 91% to 97% for controls and RR went from 47% to 69% v 84% to 88% for controls | Vaccination recommended |
| Influenza immunization of adult patients with malignant diseases29 | Hematologic malignancies (n = 21); solid tumors (n = 21); controls (n = 96) | N/A | HI titer >20 | GMT 55.6, v 110 for controls; 67% response rate v 94% for controls | Vaccination recommended |
| Influenza virus vaccine in B-cell chronic lymphocytic leukemia patients39 | CLL (n = 43); controls (n = 10) | Untreated (n = 26); Chlorambucil <20 days before vaccination (n = 17) | HI titer >20 | 56% v 100% for controls at 60 days Post-vaccination | Vaccination recommended |
| Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma40 | LPP disorders (n = 34); controls (n = 34) | Treatment with combination of multiple regimens, including cyclophosphamide, prednisone, CHOP, MOPP, ABVD, melphalan, VAD, XRT (n = 24) | HI titer >40 | 76%, 62%, and 65% seroprotection to 3 strains v 97%, 82% and 97% for controls | Vaccination recommended |
Abbreviations: XRT, radiation therapy; CLL, chronic lymphocytic leukemia; HD, Hodgkin’s lymphoma; GMT, geometric mean titre; NHL, non-Hodgkin’s lymphoma; LPP, Lymphoproliferative; MFI, mean fold increase; HI, heamagglutinin inhibition.